

# Sam Carr

Consultant

Email: [sam.carr@oxera.com](mailto:sam.carr@oxera.com)

Tel: +44 (0) 1865 253065

Languages: English



## Expertise

- Antitrust
- Antitrust Damages
- Mergers

## Sectors

- Pharmaceuticals and Life Sciences

## Profile

Sam is a member of Oxera's Competition and Health & Pharmaceuticals teams. He has worked on a wide range of competition issues in a variety of sectors, including merger investigations by both the European Commission and the UK Competition and Markets Authority (CMA), follow-on antitrust damages, abuse of dominance cases, and market investigations. He also has experience of damages quantification in the pharmaceutical sector.

Prior to joining Oxera, Sam completed a BSc in Economics at the University of Warwick, focusing on econometrics and competition economics. Since joining, he has also completed an MSc in Economics at the University of Warwick.

## Selected professional experience

- Supporting a purchaser of pharmaceuticals with quantifying the damages it is claiming from a supplier as a result of an unlawful injunction (2019–)
- Assisting a network infrastructure provider in Eastern Europe in its response to a European Commission Article 101 investigation in relation to a network sharing agreement (2019–)
- Advising a supplier of generic medicines in its response to allegations by the CMA of illegal market sharing in the market for a particular antibiotic in the UK (2019–)
- Advising a North American consumer goods wholesaler in its defence against a collective claim for damages resulting from antitrust infringements (2018–)
- Advising a large financial institution in the context of an investigation by the European Commission into an alleged breach of Article 101 in the European Government Bonds market (2017–)

- Undertaking econometric analysis for several purchasers of cathode ray tubes (CRTs) in relation to their follow-on damages claims against the global CRT cartel (2017–)
- Supported Bottomline, a financial services provider, in the successful clearance of its acquisition of Experian Payments Gateway by the CMA at phase 2 (2019–20)
- Assisted in preparing a report on behalf of the BGMA (an industry association) that assessed the functioning of the market for the supply of generic medicines in the UK (2018–19)
- Advised a generic pharmaceutical company in preparing a preliminary defence against likely allegations of excessive pricing and of engagement in anticompetitive agreements for a particular medicine in the UK (2018–19)
- Assisted a pharmaceutical company with its claim for damages resulting from unlawful regulation in the UK (2018–19)
- Supported Pfizer in Australia with quantifying the damages it owed to generic suppliers as a result of an unlawful injunction (2017–18)
- Assisted Fintrax, a financial services provider, with the successful clearance of its acquisition of GB TaxFree by the CMA (2017)
- Advised Liberty Global in the context of the successful clearance of its joint venture with Vodafone in the Netherlands by the European Commission (2016)
- Assisted with the preparation of the CMA study on the business rationales of using vertical restraints (2016)
- Advised a third party during the proposed merger between H3G and O2 being investigated by the European Commission (2015–16)
- Assisted Warner Bros in responding to a Statement of Objections from the European Commission regarding cross-border trade in audio-visual services (2015–16)
- Advised a UK distributor of memory products on a potential abuse of dominance claim regarding exclusivity agreements (2015–16)
- Assisted Scottish Power, a major UK energy supplier, in responding to the CMA's investigation into the GB energy market (2015–16)

## Qualifications

- MSc Economics, University of Warwick, UK
- BSc (Hons) Economics, University of Warwick, UK